A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Glucosamine
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Ponatinib.
Glucosamine
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Ponatinib.
Glucosamine
Interferon alfa
The risk or severity of adverse effects can be increased when Interferon alfa is combined with Ponatinib.
Glucosamine
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ponatinib.
Glucosamine
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Ponatinib.
Glucosamine
Brequinar
The risk or severity of adverse effects can be increased when Brequinar is combined with Ponatinib.
Glucosamine
2-Methoxyethanol
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Ponatinib.
Glucosamine
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Ponatinib.
Glucosamine
Castanospermine
The risk or severity of adverse effects can be increased when Castanospermine is combined with Ponatinib.
Glucosamine
Stepronin
The risk or severity of adverse effects can be increased when Stepronin is combined with Ponatinib.
Glucosamine
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Ponatinib.
Bevantolol
Relugolix
The serum concentration of Relugolix can be increased when it is combined with Enzalutamide.
Bevantolol
Gallium Ga-68 gozetotide
Enzalutamide may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent.
Bevantolol
Berotralstat
The serum concentration of Berotralstat can be increased when it is combined with Enzalutamide.
Bevantolol
Pralsetinib
The serum concentration of Pralsetinib can be increased when it is combined with Enzalutamide.
Bevantolol
Satralizumab
The serum concentration of Enzalutamide can be decreased when it is combined with Satralizumab.
Bevantolol
Oliceridine
The serum concentration of Oliceridine can be decreased when it is combined with Enzalutamide.
Bevantolol
Abametapir
The serum concentration of Enzalutamide can be increased when it is combined with Abametapir.
Bevantolol
Fostemsavir
The serum concentration of Fostemsavir can be decreased when it is combined with Enzalutamide.
Bevantolol
Lurbinectedin
The serum concentration of Lurbinectedin can be decreased when it is combined with Enzalutamide.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3